Onconetix, Inc. (ONCO)
| Market Cap | 893.34K |
| Revenue (ttm) | 1.87M |
| Net Income (ttm) | -51.60M |
| Shares Out | 8.29M |
| EPS (ttm) | -71.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 68,473,861 |
| Open | 0.103 |
| Previous Close | 0.106 |
| Day's Range | 0.101 - 0.150 |
| 52-Week Range | 0.087 - 21.400 |
| Beta | 3.27 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 19, 2025 |
About ONCO
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartere... [Read more]
Financial Performance
Financial StatementsNews
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the re...
Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress
CINCINNATI, March 19, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) (“Onconetix” or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the re...
Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing
Cincinnati, OH, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (the “Company”) announced that it received a letter from The Nasdaq Capital Market (“Nasdaq”) on December 6, 2024 indic...
Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board
SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune r...
Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit
CINCINATTI, OH., Oct. 03, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Onconetix, Inc. (Nasdaq: ONCO), please note that in the first paragraph of the release, ...
Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit
CINCINATTI, Oh., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or “the Company”) (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the ...
Crude Oil Rises; Onconetix Shares Spike Higher
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling more than 100 points on Friday.
Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders
CINCINNATI, Ohio, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and c...
Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds
CINCINNATI, July 15, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (“Onconetix” or the “Company”) (Nasdaq: ONCO), today announced the closing of the previously announced exercise of certain existing warran...
Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds
CINCINNATI, Ohio, July 11, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (“Onconetix” or the “Company”) (Nasdaq: ONCO), today announced it has entered into definitive agreements for the immediate exercise ...
Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors
CINCINNATI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), a commercial stage biotechnology company focused on developing and commercializing therape...
Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders
CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: BWV) ("Onconetix" or the “Company”) today issued the following shareholder letter from the Company's Chief Executive Officer, Dr...
Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™
Transaction strengthens commercial business with addition of diagnostics product and initial focus on prostate cancer Transaction strengthens commercial business with addition of diagnostics product a...
Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company
Transaction will Advance Company's Shift in Business Strategy Aligned with Life Sciences Industry Expertise of New Leadership Team Transaction will Advance Company's Shift in Business Strategy Aligned...
Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)
CINCINNATI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced that it has received a letter from the Nasdaq Stock Market, LLC ("Nasdaq")...
Blue Water Biotech Issues Letter to Shareholders
CINCINNATI, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today issued the following shareholder letter from the Company's Chief Executive Officer D...
Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO
CINCINNATI, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV), which is focused on developing and commercializing transformational therapies to address significant global health...
Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q
CINCINNATI, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology and pharmaceutical company spanning multiple sectors, today announced that it re...
Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds
CINCINNATI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), today announced the closing of its previously announced exercise of certain existi...
Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds
CINCINNATI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. ("Blue Water" or the “Company”) (Nasdaq: BWV), today announced it has entered into a definitive agreement for the exercise of cer...
Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians
CINCINNATI, July 31, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and commercializi...
Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®
CINCINNATI, July 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and commercializi...
Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities
CINCINNATI, July 17, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company focused on developing and commercializi...
Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support
Pharmaceutical consulting firm to provide Blue Water with access to healthcare payers and PBMs Pharmaceutical consulting firm to provide Blue Water with access to healthcare payers and PBMs
Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products
First state license is a key achievement as Blue Water continues to expand its business into commercial activities First state license is a key achievement as Blue Water continues to expand its busine...